Drug updated on 11/13/2023

Dosage FormInjection (intravenous; 500 mg/10 mL, 120 mg/2.4 mL)
Drug ClassProgrammed death-ligand 1 blocking antibodies
Ongoing and Completed


  • For the treatment of adult patients with unresectable, Stage III non-small cell lung cancer (NSCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.
  • Indicated in combination with etoposide and either carboplatin or cisplatin, as first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).
  • Indicated in combination with tremelimumab-actl and platinum-based chemotherapy, for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic tumor aberrations.
  • Indicated in combination with gemcitabine and cisplatin, as treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC).
  • Indicated in combination with tremelimumab-actl, for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC).

Product Monograph / Prescribing Information

Document TitleYearSource
Imfinzi (durvalumab) Prescribing Information.2022AstraZeneca Pharmaceuticals LP, Wilmington, DE

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Clinical, pharmacoeconomic, and stakeholder input combined report.2023CADTH
Addition of immune checkpoint inhibitors to chemotherapy vs chemotherapy alone as first-line treatment in extensive-stage small-cell lung carcinoma: a systematic review and meta-analysis. 2022Oncology and Therapy
Impact of PD1 and PDL1 immunotherapy on non-small cell lung cancer outcomes: a systematic review.2022Thorax
How immunotherapy modified the therapeutic scenario of endometrial cancer: a systematic review.2022Frontiers in Oncology
PD-1/PD-L1 inhibitor monotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck: a meta-analysis.2022American Journal of Otolaryngology
Real-World Safety and Efficacy of Consolidation Durvalumab After Chemoradiation Therapy for Stage III Non-small Cell Lung Cancer: A Systematic Review and Meta-analysis.2022International journal of radiation oncology, biology, physics.
Comparison of atezolizumab, durvalumab, pembrolizumab, and nivolumab as first-line treatment in patients with extensive-stage small cell lung cancer: a systematic review and network meta-analysis.2021Medicine
Comparative efficacy and safety of immunotherapeutic regimens with PD-1/PD-L1 inhibitors for previously untreated extensive-stage small cell lung cancer: A systematic review and network meta-analysis. 2021Current Oncology
Clinical and Pharmacoeconomic combined report: durvalumab (Imfinzi). 2021CADTH
The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis. 2021BMC Cancer
Meta-analysis of immune-related adverse events in phase 3 clinical trials assessing immune checkpoint inhibitors for lung cancer.2021Clinical Reviews in Oncology/Hematology
Efficacy and safety of first-line immunotherapy in combination with chemotherapy for patients with extensive-stage small cell lung cancer: a systematic review and network meta-analysis.2020Journal of Oncology
Systematic review and network meta-analysis of immune checkpoint inhibitors in combination with chemotherapy as a first-line therapy for extensive-stage small cell carcinoma. 2020Cancers
Rationale and outcomes for neoadjuvant immunotherapy in urothelial carcinoma of the bladder.2020European Urology Oncology
Final clinical guidance report: durvalumab (Imfinzi) for non-small cell lung cancer.2019CADTH
The differences in the safety and tolerability of immune checkpoint inhibitors as treatment for non-small cell lung cancer and melanoma: network meta-analysis and systematic review.2019Frontiers in Pharmacology

Clinical Practice Guidelines